Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
about
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging conceptsCan microRNAs improve the management of lung cancer patients? A clinician's perspectiveBevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: A multi-center study of the Fukushima lung cancer association grouThe role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancerRisk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.The major thoracic vascular invasion of lung cancer.MicroRNAs as lung cancer biomarkersIdentification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2.Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapyDynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy.Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.Biomarkers of response and resistance to antiangiogenic therapy.Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.Angiogenesis inhibitors in the treatment of non-small cell lung cancerA Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533Therapeutic antibodies against cancer.Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of expertsTumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumabLung cancer: Biology and treatment options.Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response?Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor.Parameters for individualizing systemic therapy in non-small cell lung cancerEfficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population.Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysisPractical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases.Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancerTimely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist.Bevacizumab in non-small-cell lung cancer: a review.Risk profile of bevacizumab in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials.Ancillary testing in lung cancer diagnosis.Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.Vascular-disrupting agents in oncology.Complications of targeted drug therapies for solid malignancies: manifestations and mechanismsRe-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents.Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.The clonal evolution and therapeutic approaches of lung cancer.Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
P2860
Q24658198-ABD5BDD6-5803-4BF0-9D9E-B69E7A8666F2Q26863654-49C555EB-9A34-4AF3-B73F-BAFB5109FD07Q26999304-156A2B0D-7436-47FF-AEBD-0A18A8F19C8FQ33396369-FB9D5717-6AAE-4D94-9B37-E3BABE9C0A3DQ33442591-30C5D651-926D-4DD0-9CD6-C749AF66F130Q33565294-E350E673-2792-45B8-9A7D-E828F56C93C2Q33795896-78700340-630D-4470-9BC5-31BAE41713E0Q33835552-537F4227-4C61-4C21-A7AE-E558E360EC4BQ34031213-E8F8C2FB-7AFB-4D03-B2D1-31C5144154C6Q34102071-6AE6847D-7EC2-4F7B-97DE-8FD100CD2D96Q34133236-27EBFC67-43BA-483D-939F-8F24160ED964Q34523039-0505495C-B682-4E4C-BAF9-DAAFCFDCA700Q34626688-59E6D06B-C57D-42F7-BD50-66864756FF46Q34673567-187ACC9C-4B8D-47AD-9202-42A8B725B0EDQ34854658-2C2FBAC3-F67F-4154-8EB7-419E05B4BE8DQ35076198-D5363D4E-025C-400A-A88B-2746B00487A4Q35836792-C8CCD11A-EA6E-4C3B-B530-06C39FA8B9CCQ35908498-87EAA9B1-D34D-4107-8440-D0C17AB69D58Q35909225-9FC09832-F23A-408B-A7B6-C7AA49DA390BQ36084854-B6BF86E4-5E07-4B3E-BCA9-5B0B5F3CC51AQ36301449-1F1CC74A-90E5-4EF4-988C-45CEE3EB9FA8Q36328370-29AAC356-96FE-4D32-9C8D-18C4FE8FD85CQ36357248-4FB7CDD2-7DE7-437B-938B-46CA2B7AA21EQ36439535-D8F3ED46-847F-4056-AADC-568ABD89FD66Q37398845-54712A96-C58C-4B2F-B2D3-38D2262F6B38Q37532320-5DCF509F-07F4-4B58-91C0-0051065F43ECQ37544351-059C785F-40B7-466C-9CB8-94C95411FB9AQ37566624-3DFA1A22-6FF3-484A-AAE2-830BD1FD07EBQ37670436-6E6FE5E3-2E7C-4998-BC28-4180A0C7BB23Q37926954-F8EFCF2B-660F-44F3-B1C6-FB1527162966Q37931886-C686DA18-1345-4DD8-A231-118CFE89E9D1Q37956392-384E6C38-CCFD-4F11-8C94-1DB3346F21F1Q37977440-5FE0ACD7-9EC5-4120-8F6A-24C5973160B9Q38062459-6C45BC37-29BB-4A05-94E6-8792904D3D3DQ38073812-877774D5-E184-4B72-B267-A1BD28153D1AQ38084265-2962FF3D-9651-4F00-AAAE-A71B7B1F0EFEQ38099562-8A01CD56-782C-4034-B07A-F899EF0C60DAQ38153445-572832AE-97AE-4998-917D-957543CE817EQ38196755-6BB985B8-45E9-4A68-87F9-27549666631AQ38390200-9D97D0F0-160D-41B0-9E72-C086FA9B3211
P2860
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Retrospective evaluation of th ...... d Paclitaxel plus bevacizumab.
@ast
Retrospective evaluation of th ...... d Paclitaxel plus bevacizumab.
@en
type
label
Retrospective evaluation of th ...... d Paclitaxel plus bevacizumab.
@ast
Retrospective evaluation of th ...... d Paclitaxel plus bevacizumab.
@en
prefLabel
Retrospective evaluation of th ...... d Paclitaxel plus bevacizumab.
@ast
Retrospective evaluation of th ...... d Paclitaxel plus bevacizumab.
@en
P2093
P2860
P356
P1476
Retrospective evaluation of th ...... d Paclitaxel plus bevacizumab.
@en
P2093
Alan B Sandler
David H Johnson
Isaiah Dimery
Joan H Schiller
Julie Brahmer
Lisa I Wang
Meghna Samant
Robert Gray
P2860
P304
P356
10.1200/JCO.2008.16.2412
P407
P577
2009-02-17T00:00:00Z